Fresenius Medical Care, a global leader in products and services for individuals with kidney disease, has inaugurated its first training center in Korea. This significant development aims to provide comprehensive education programs, sharing invaluable knowledge and expertise in renal care, critical care, and cutting-edge treatment strategies with healthcare professionals. The center’s training programs and events are designed to foster a deeper understanding within the healthcare industry, ultimately enhancing patient care standards.
The opening ceremony, held on June 24th, was a landmark event led by Professor Yang Chulwoo, President of the Korean Society of Nephrology (KSN), and Clare Kim, Managing Director of Fresenius Medical Care Korea, alongside esteemed members of the KSN executive committee.
The Fresenius Medical Care Training Center stands as the first healthcare education facility in Korea operated by a dialysis product provider. It is dedicated to supporting the professional growth of doctors, nurses, and clinical technicians by offering access to the latest advancements in renal care knowledge and practical skills. Situated in Yeouido, the bustling city center of Seoul, the center provides a prime location for healthcare professionals to engage in training and upskilling programs. A key feature is the opportunity for hands-on experience with Fresenius Medical Care’s advanced medical equipment. This includes technologies used in hemodialysis (HD), automated peritoneal dialysis (APD), and continuous renal replacement therapy (CRRT), ensuring participants gain practical competence with industry-leading tools. Certified trainers from Fresenius Medical Care, in collaboration with regional clinical education experts from across the Asia Pacific region, will deliver best-in-class training, solidifying the center’s commitment to excellence in renal care education.
Fresenius Medical Care Korea has pledged continuous support for healthcare professional education through this Training Center. The center will host regular academic conferences, including the Advanced Renal Education Program (AREP), Fresenius Medical Care Korea’s flagship annual education initiative for renal care professionals. Furthermore, specialized training for nephrology nurses focused on the unique needs of dialysis patients will be a core offering. Recognizing the diverse needs within the field, the Fresenius Medical Care Dialysis Training Program also provides tailored educational opportunities for healthcare professionals specializing in specific treatment modalities such as Peritoneal Dialysis (PD), Hemodialysis (HD), and Continuous Renal Replacement Therapy (CRRT). This comprehensive approach ensures that all aspects of dialysis care are covered, from foundational knowledge to advanced specialty skills.
Professor Yang Chulwoo, President of the KSN, expressed strong support for the initiative, stating, “KSN welcomes and appreciates Fresenius Medical Care’s efforts in establishing the training center and offering comprehensive training programs for healthcare professionals. We anticipate that this center will significantly contribute to the long-term improvement of medical service quality for patients in Korea.”
Clare Kim, Managing Director of Fresenius Medical Care Korea, emphasized the center’s role in professional development, stating, “The Fresenius Medical Care Training Center will equip healthcare professionals with high-standard, systematic training, empowering them to enhance their expertise in renal and critical care. Looking ahead, we are dedicated to offering extensive academic programs to support the continuous development of healthcare professionals. Our commitment extends to delivering top-tier products and services that effectively address the evolving needs of patients, the healthcare community, and the broader industry.”
Harry de Wit, President and CEO of Fresenius Medical Care Asia Pacific, highlighted the company’s global commitment and expertise: “As the world’s leading provider of dialysis products and services, and with a cutting-edge portfolio in critical care, Fresenius Medical Care is committed to sharing its deep expertise and extensive experience with our healthcare professional partners. By supporting their professional growth and development through the Fresenius medical care dialysis training program, we are investing in ensuring consistently high standards of care for patients. This ultimately allows us to advance our mission – to create a future that offers a better quality of life, every day, for patients around the world.”
About Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. Globally, approximately 3.7 million patients depend on dialysis treatment regularly. Through its extensive network of 4,110 dialysis clinics, Fresenius Medical Care delivers dialysis treatments to 344,476 patients worldwide. The company is also a leading manufacturer of dialysis products, including dialysis machines and dialyzers. Beyond its core focus on the Renal Care Continuum, Fresenius Medical Care is actively expanding into complementary healthcare areas and the critical care sector. Fresenius Medical Care is publicly listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
For further details, please visit the company’s website at www.freseniusmedicalcare.asia.
Disclaimer:
This release includes forward-looking statements that involve various risks and uncertainties. Actual outcomes may differ materially from those projected in these statements due to numerous factors. These factors include, but are not limited to, changes in business, economic, and competitive landscapes, legal and regulatory changes, the success of clinical studies, currency exchange rate fluctuations, uncertainties related to litigation or investigations, and the availability of financing. For a comprehensive understanding of these risks and uncertainties, please refer to Fresenius Medical Care AG & Co. KGaA’s filings with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA undertakes no obligation to revise or update any forward-looking statements contained within this release.
